Authors : Zeba Sultana; Shaik Nikhath Faheem

Volume/Issue : Volume 9 - 2024, Issue 5 - May

Google Scholar : https://tinyurl.com/2yyf9dn5

Scribd : https://tinyurl.com/46meb6y3

DOI : https://doi.org/10.38124/ijisrt/IJISRT24MAY510

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Blood pressure, which includes ischemic heart disease, stroke, and chronic kidney disease, is the leading preventable cause of death from cardiovascular illnesses on a global scale. Worldwide, arterial hypertension ranks first among cardiovascular diseases (CVDs) and has done so for a long time. One of the first drugs to target hypertension using small interfering RNA (siRNA) technology is zilebesiran. Zilebesiran, an RNA interference therapy drug now in development, binds strongly to the hepatic asialoglycoprotein receptor. A therapeutic target for hypertension, it aims to decrease angiotensinogen production by measuring hepatic angiotensinogen messenger RNA (mRNA) quantities. Zilebesiran is a novel, ground-breaking siRNA therapy for the treatment of hypertension that is now in the second stage of clinical studies. How much of it crosses the placenta and whether it might be utilized to treat preeclampsia should be addressed in future research.

Keywords : Zilebesiran, Cardiovascular diseases, Renin- angiotensin-aldosterone system, N-acetylgalactosamine (GalNAc), Angiotensinogen (AGT).

References :

1. Ranasinghe, P., Addison, M. L., & Webb, D. J. (2022). Small interfering RNA therapeutics in hypertension: A viewpoint on vasopressor and vasopressor‐sparing strategies for counteracting blood pressure lowering by angiotensinogen–targeting small interfering RNA. Journal of the American Heart Association, 11(20).
2. Wang, G., Grosse, S. D., & Schooley, M. W. (2017). Conducting research on the economics of hypertension to improve cardiovascular health. American Journal of Preventive Medicine, 53(6), S115–S117.
3. Ettehad, D., Emdin, C. A., Kiran, A., Anderson, S. G., Callender, T., Emberson, J., Chalmers, J., Rodgers, A., & Rahimi, K. (2016). Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet, 387(10022), 957–967.
4. Srikanth, S., Mondal, A., Aggarwal, S., Naga Ruthvika Alle, O., Parth, R., Nayak, A., & Vyas, R. (2024). Key hypertension breakthroughs and emerging trends from the AHA’s scientific sessions. Current Problems in Cardiology, 49.
5. Kate, M. (2024). Progress towards improving blood pressure control. Nature Reviews Nephrology, 20(2), 73–74.
6. Guo, S., Zhang, M., & Huang, Y. (2023). Three ‘E’ challenges for siRNA drug development. Trends in Molecular Medicine.
7. Achelrod, D., Wenzel, U., & Frey, S. (2015). Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. American Journal of Hypertension, 28(3), 355–361.
8. Ampofo, A. G., & Boateng, E. B. (2020). Beyond 2020: Modelling obesity and diabetes prevalence. Diabetes Research and Clinical Practice, 167(108362), 108362.
9. Sarzani, R., Spannella, F., Pentima, C. D., Giulietti, F., Landolfo, M., & Allevi, M. (2024). Molecular Therapies in Cardiovascular Diseases: Small Interfering RNA in Atherosclerosis, Heart Failure, and Hypertension. International Journal of Molecular Sciences, 25(1).
10. Ye, D., Edwyn, O., Cruz-López, H.-C., Tu, I., & Zlatev, A. H. (2023). Targeting Angiotensinogen With N -Acetylgalactosamine-Conjugated Small Interfering RNA to Reduce Blood Pressure. Arteriosclerosis, Thrombosis, and Vascular Biology, 43, 2256–2264.
11. Addison, M. L., Ranasinghe, P., & Webb, D. J. (2023). Emerging insights and future prospects for therapeutic application of siRNA targeting angiotensinogen in hypertension. Expert Review of Clinical Pharmacology, 1–9.
12. Liuzzo, G., & Volpe, M. (2023). Silencing liver angiotensinogen synthesis as a novel approach to hypertension management: promises and challenges. European Heart Journal, 44(40), 4217–4219.
13. Touyz Rhian, M. (2023). Silencing Angiotensinogen in Hypertension. N Engl J Med, 389, 278–281.
14. Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., Barengo, N. C., Beaton, A. Z., Benjamin, E. J., Benziger, C. P., Bonny, A., Brauer, M., Brodmann, M., Cahill, T. J., Carapetis, J., Catapano, A. L., Chugh, S. S., Cooper, L. T., Coresh, J., … Fuster, V. (2020). Global burden of cardiovascular diseases and risk factors, 1990–2019. Journal of the American College of Cardiology, 76(25), 2982–3021.
15. Choudhry, N. K., Kronish, I. M., Vongpatanasin, W., Ferdinand, K. C., Pavlik, V. N., Egan, B. M., Schoenthaler, A., Houston Miller, N., Hyman, D. J., & on behalf of the American Heart Association Council on Hypertension; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. (2022). Medication adherence and blood pressure control: A scientific statement from the American heart association. Hypertension, 79(1).
16. Desai, A. S., Webb, D. J., Taubel, J., Casey, S., Cheng, Y., Robbie, G. J., Foster, D., Huang, S. A., Rhyee, S., Sweetser, M. T., & Bakris, G. L. (2023). Zilebesiran, an RNA interference therapeutic agent for hypertension. The New England Journal of Medicine, 389(3), 228–238.
17. Huang, S. A., Taubel, J., Fiore, G., Dewland, P., Bakris, G. L., Desai, A. S., Cheng, Y., Agarwal, S., Harrop, J., Nguyen, H. V., Lu, J., Foster, D., Vaishnaw, A., & Kim, J. B. (2020). Abstract 14387: Dose-related reductions in blood pressure with a RNA interference (RNAi) therapeutic targeting angiotensinogen in hypertensive patients: Interim results from a first-in-human phase 1 study of ALN-AGT01. Circulation, 142(Suppl_3).
18. Desai, A. S., Webb, D. J., Taubel, J., Casey, S., Cheng, Y., Robbie, G. J., Foster, D., Huang, S. A., Rhyee, S., Sweetser, M. T., & Bakris, G. L. (2023b). Zilebesiran, an RNA interference therapeutic agent for hypertension. The New England Journal of Medicine, 389(3), 228–238.
19. Braunwald, E. (2023). Inhibition of angiotensinogen in the treatment of hypertension. European Heart Journal.
20. Povlsen, A. L., Grimm, D., Wehland, M., Infanger, M., & Krüger, M. (2020). The vasoactive Mas receptor in essential hypertension. Journal of Clinical Medicine, 9(1), 267.